Literature DB >> 70689

Immunoglobulin-containing cells in multiple-sclerosis plaques.

M M Esiri.   

Abstract

An immunoperoxidase method has been used to study the content of immunoglobulin-containing cells in 100 multiple sclerosis (M.S.) plaques and 100 adjacent areas of normally myelinated tissue obtained post mortem from ten patients with M.S. Immunoglobulin-containing cells were significantly more numerous in plaques than in non plaques and in recent plaques as compared with old plaques. More of the cells in plaques contained demonstrable light chain than heavy chain, and the kappa/lambda ratio was significantly higher in recent and moderately recent plaques than in normally myelinated tissue. 92% of the demonstrable heavy chain present in cells was IgG, 7-3% was IgA, and 0-7% IgM. It is suggested that each plaque in M.S. may be associated with local proliferation (a clone or small number of clones of immunoglobulin-producing cells, producing predominantly IgG heavy chains with kappa light chains, and occasionally with lambda light chains.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 70689      PMCID: PMC8334654          DOI: 10.1016/s0140-6736(77)91603-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  41 in total

1.  Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.

Authors:  R T Naismith; L Piccio; J A Lyons; J Lauber; N T Tutlam; B J Parks; K Trinkaus; S K Song; A H Cross
Journal:  Neurology       Date:  2010-06-08       Impact factor: 9.910

Review 2.  Rituximab in a patient with ankylosing spondylitis with demyelinating disease: a case report and review of the literature.

Authors:  Mohammed A Omair; Khalid A Alnaqbi; Peter Lee
Journal:  Clin Rheumatol       Date:  2012-05-27       Impact factor: 2.980

Review 3.  What's new in the pathogenesis of multiple sclerosis? A review.

Authors:  S J Chataway
Journal:  J R Soc Med       Date:  1989-03       Impact factor: 5.344

Review 4.  Humoral immunity in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis.

Authors:  Anne H Cross; Jennifer L Stark
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 5.  B-cells and humoral immunity in multiple sclerosis. Implications for therapy.

Authors:  Sangjin Oh; Cornelia Cudrici; Takahiro Ito; Horea Rus
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

6.  Lipocalin-2 protein deficiency ameliorates experimental autoimmune encephalomyelitis: the pathogenic role of lipocalin-2 in the central nervous system and peripheral lymphoid tissues.

Authors:  Youngpyo Nam; Jong-Heon Kim; Minchul Seo; Jae-Hong Kim; Myungwon Jin; Sangmin Jeon; Jung-wan Seo; Won-Ha Lee; So Jin Bing; Youngheun Jee; Won Kee Lee; Dong Ho Park; Hyun Kook; Kyoungho Suk
Journal:  J Biol Chem       Date:  2014-05-07       Impact factor: 5.157

7.  Altered regulation of mitogen responsiveness by suppressor cells in multiple sclerosis.

Authors:  R L Gonzalez; P C Dau; L E Spitler
Journal:  Clin Exp Immunol       Date:  1979-04       Impact factor: 4.330

8.  Pluripotential hemopoietic stem cells in adult mouse brain.

Authors:  P F Bartlett
Journal:  Proc Natl Acad Sci U S A       Date:  1982-04       Impact factor: 11.205

9.  Antibody to myelin basic protein in extracts of multiple sclerosis brain.

Authors:  C C Bernard; V B Randell; L B Horvath; P R Carnegie; I R Mackay
Journal:  Immunology       Date:  1981-07       Impact factor: 7.397

10.  B cells and monocytes from patients with active multiple sclerosis exhibit increased surface expression of both HERV-H Env and HERV-W Env, accompanied by increased seroreactivity.

Authors:  Tomasz Brudek; Tove Christensen; Lars Aagaard; Thor Petersen; Hans J Hansen; Anné Møller-Larsen
Journal:  Retrovirology       Date:  2009-11-16       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.